Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
J Gastroenterol Hepatol
    October 2026
  1. HUANG CF, Liang PC, Huang CK, Stec M, et al
    The Clinical Utility of Adding Laminin Gamma 2 Monomer to the PAGE-B Score for Hepatocellular Carcinoma Surveillance in Chronic Hepatitis B.
    J Gastroenterol Hepatol. 2026 Oct 8. doi: 10.1111/jgh.70792.
    >> Share

  2. HONMA Y, Shimose S, Ito T, Saeki I, et al
    Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab.
    J Gastroenterol Hepatol. 2026 Oct 5. doi: 10.1111/jgh.70793.
    >> Share

  3. ABBARH S, Sawaf B, Cerqueira TL, Huttner HB, et al
    Association of Aspirin With Improved Clinical Outcomes and Survival in Patients With Compensated Cirrhosis: A Propensity Score-Matched Study of 25 782 Individuals.
    J Gastroenterol Hepatol. 2026 Oct 1. doi: 10.1111/jgh.70780.
    >> Share

    September 2026
  4. OUCHI K, Ninomiya M, Tsuruoka M, Inoue J, et al
    Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage.
    J Gastroenterol Hepatol. 2026 Sep 28. doi: 10.1111/jgh.70765.
    >> Share

  5. WU C, Gao J, Gao B, Wang K, et al
    Demethylzeylasteral Targets the Sp1/AGAP2 Axis to Impair Autophagic Flux and Induce Apoptosis in Hepatic Stellate Cells.
    J Gastroenterol Hepatol. 2026 Sep 27. doi: 10.1111/jgh.70778.
    >> Share

  6. LEE J, Cha JH, Cho HS, Yang H, et al
    PNPLA3 Is Associated With Hepatocellular Carcinoma, While a Five-Variant Polygenic Risk Score Shows Limited Discrimination in Korean Patients With MASLD.
    J Gastroenterol Hepatol. 2026 Sep 27. doi: 10.1111/jgh.70762.
    >> Share

  7. LAU SY, Chan WK
    Letter to Editor-In Response to "The Malaysian Society of Gastroenterology and Hepatology Consensus Statements on Prevention and Early Detection of Hepatocellular Carcinoma in Malaysia".
    J Gastroenterol Hepatol. 2026 Sep 22. doi: 10.1111/jgh.70770.
    >> Share

  8. BALOCH MSA, Rehman QSU, Saleem MZ
    Re: The Malaysian Society of Gastroenterology and Hepatology Consensus Statements on Prevention and Early Detection of Hepatocellular Carcinoma in Malaysia.
    J Gastroenterol Hepatol. 2026 Sep 21. doi: 10.1111/jgh.70771.
    >> Share

  9. LAU G
    Translational Hepatology From Bedside to Global Policy: How Robust Clinical and Translational Research Reshapes Global Practice Guidelines and Patient Outcomes.
    J Gastroenterol Hepatol. 2026 Sep 21. doi: 10.1111/jgh.70742.
    >> Share

  10. WU Y
    Comment on "AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis".
    J Gastroenterol Hepatol. 2026 Sep 15. doi: 10.1111/jgh.70748.
    >> Share

  11. BHAWISH R, Ansar S
    Comment on "Smoking and Risk of Hepatic Steatosis Within the MASLD Spectrum in Korean Young Adults".
    J Gastroenterol Hepatol. 2026 Sep 3. doi: 10.1111/jgh.70721.
    >> Share

  12. LEE A, Han CI, Yang K, Yang H, et al
    Emerging Indices Outperform Traditional Fibrosis Scores in Young Metabolic Dysfunction-Associated Steatotic Liver Disease Across Divergent Screening Goals.
    J Gastroenterol Hepatol. 2026;41:2925-2937.
    >> Share

  13. WONG VW
    MAFLD/MASLD: Past, Present, and Future.
    J Gastroenterol Hepatol. 2026;41:2882-2892.
    >> Share

  14. GAO F, Zhang Y, Ding Y, Li Y, et al
    Noninvasive Detection of MASH and Fibrotic Burden Using Ultrasound-Derived LIID and LSM in MASLD: A Multicenter Study.
    J Gastroenterol Hepatol. 2026;41:2843-2852.
    >> Share

  15. CHON YE, Han KD, Yang JD, Park JY, et al
    Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy.
    J Gastroenterol Hepatol. 2026;41:2913-2924.
    >> Share

  16. ZHAO X, Peng S, Zhong K, Wang M, et al
    Macrophage ACAT1 Aggravates Alcohol-Associated Liver Disease by Inducing Mitochondrial Damage and NLRP3 Activation.
    J Gastroenterol Hepatol. 2026;41:2938-2952.
    >> Share

  17. SOGABE M, Okahisa T, Kagawa M, Shinomiya R, et al
    Comparing the Effect of Changes in Alcohol Intake on Liver Fibrosis Risk Scores Among Patients With Two Distinct Types of Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:2697-2708.
    >> Share

  18. ALKUWAITI MA, Al-Harbi FA, Alsaif AK, AlSughayyir ZM, et al
    GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations.
    J Gastroenterol Hepatol. 2026;41:2862-2881.
    >> Share

    August 2026
  19. YI H, Lee HW, Shin JI, Lee HW, et al
    Comparable Predictive Performance of Non-VCTE-Based Machine Learning Model for HBV-Infected Hepatocellular Carcinoma Risk.
    J Gastroenterol Hepatol. 2026 Aug 27. doi: 10.1111/jgh.70686.
    >> Share

  20. TADA T, Matono T, Kumada T
    Response to the Letter Regarding "Methodological Considerations in Real-World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma".
    J Gastroenterol Hepatol. 2026 Aug 18. doi: 10.1111/jgh.70674.
    >> Share

  21. JIANG J, Wang B, Wang Q, Ma X, et al
    AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis.
    J Gastroenterol Hepatol. 2026 Aug 16. doi: 10.1111/jgh.70670.
    >> Share

  22. OGHENETEGA A, Ghaffar A, Khokhar ME, Opene C, et al
    Methodological Considerations in Real-World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2026 Aug 14. doi: 10.1111/jgh.70673.
    >> Share

  23. LAU SY, Kok VS, Tan SS, Adnan SD, et al
    The Malaysian Society of Gastroenterology and Hepatology Consensus Statements on Prevention and Early Detection of Hepatocellular Carcinoma in Malaysia.
    J Gastroenterol Hepatol. 2026 Aug 14. doi: 10.1111/jgh.70643.
    >> Share

  24. NAJAF DE, Siddique A, Shah HM, Ullah T, et al
    Beyond Repositionability: Rethinking Clinical Value and Stent Selection in EUS-Guided Hepaticogastrostomy.
    J Gastroenterol Hepatol. 2026 Aug 14. doi: 10.1111/jgh.70666.
    >> Share

  25. STRASSER SI, Thompson AJ, Gupta R, Lubel J, et al
    Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective.
    J Gastroenterol Hepatol. 2026 Aug 9. doi: 10.1111/jgh.70616.
    >> Share

  26. LAU KC, Wong VW, Kong AP, Wong GL, et al
    Hepatic Steatosis and Low-Density Lipoprotein Cholesterol Response After Statin Initiation: A Prospective Cohort Analysis.
    J Gastroenterol Hepatol. 2026 Aug 7. doi: 10.1111/jgh.70656.
    >> Share

  27. TADA T, Matono T, Kumada T
    Response to the Letter Regarding "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial".
    J Gastroenterol Hepatol. 2026 Aug 6. doi: 10.1111/jgh.70654.
    >> Share

  28. GILANI SAZ, Naseer M
    Post-ERCP Outcomes in Cirrhotics Patients With Thrombocytopenia: A Propensity-Matched Retrospective Comparative Analysis.
    J Gastroenterol Hepatol. 2026 Aug 6. doi: 10.1111/jgh.70638.
    >> Share

  29. JESWANI H, Jeswani AK
    Comment on Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.
    J Gastroenterol Hepatol. 2026 Aug 4. doi: 10.1111/jgh.70655.
    >> Share

  30. WANG CW, Huang CF, Yeh ML, Liang PC, et al
    Association Between ADH1B rs1229984 Genetic Polymorphism and Hepatic Steatosis Assessed by CT Attenuation: A Mediation Analysis of Central Obesity in MASLD.
    J Gastroenterol Hepatol. 2026 Aug 4. doi: 10.1111/jgh.70632.
    >> Share

    July 2026
  31. CHOWDHARY R, Prasad S, Koo TH, Liu BDX, et al
    Burden of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive US Healthcare Analysis.
    J Gastroenterol Hepatol. 2026 Jul 22. doi: 10.1111/jgh.70609.
    >> Share

  32. MUKAI S, Sofuni A, Tsuchiya T, Tanaka R, et al
    Prospective Clinical Evaluation of a Novel Repositionable Plastic Stent for Endosonography-Guided Hepaticogastrostomy With or Without Antegrade Stenting (With Videos).
    J Gastroenterol Hepatol. 2026 Jul 19. doi: 10.1111/jgh.70567.
    >> Share

  33. KUMAR S, Shaikh MM
    Methodological Considerations in Interpreting IL-15 Plus Thymosin alpha1 Therapy for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2026 Jul 17. doi: 10.1111/jgh.70607.
    >> Share

  34. ULLAH W, Ashok K, Jawad M, Antar AS, et al
    Comments on IL-15 Plus Thymosin alpha1 Reduces Senescent Hepatic CD8+ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
    J Gastroenterol Hepatol. 2026 Jul 16. doi: 10.1111/jgh.70592.
    >> Share

  35. STIRRAT T, Hu B, Flatley M, Apte S, et al
    Gender Authorship in Gastroenterology and Hepatology: Trends and Persistent Seniority Gaps.
    J Gastroenterol Hepatol. 2026 Jul 14. doi: 10.1111/jgh.70552.
    >> Share

  36. LIN SH, Wu JL, Tsai YN, Tseng CH, et al
    Comparative Effectiveness and Safety of Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab as First-Line Systemic Therapy for Hepatocellular Carcinoma: A Real-World Study.
    J Gastroenterol Hepatol. 2026 Jul 10. doi: 10.1111/jgh.70555.
    >> Share

  37. JEE Y, Lee SJ, Chun HS, Shin HY, et al
    Smoking and Risk of Hepatic Steatosis Within the MASLD Spectrum in Korean Young Adults.
    J Gastroenterol Hepatol. 2026 Jul 9. doi: 10.1111/jgh.70550.
    >> Share

  38. CHE K, Lin K, Li S
    Comments on "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial".
    J Gastroenterol Hepatol. 2026 Jul 7. doi: 10.1111/jgh.70558.
    >> Share

  39. HE C, Wei Y, Zheng K, Wang X, et al
    Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial.
    J Gastroenterol Hepatol. 2026 Jul 7. doi: 10.1111/jgh.70554.
    >> Share

  40. OKUWAKI K, Watanabe M, Uojima H, Hidaka H, et al
    Randomized Controlled Trial of Endoscopic Ultrasound-Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens.
    J Gastroenterol Hepatol. 2026;41:2130-2137.
    >> Share

    June 2026
  41. ZENG C, Jiang H, Zhong Y, Wan L, et al
    Toward the Era of Precision Immunotherapy: The Clinical Landscape and Future Directions of mRNA Vaccines for the Treatment of Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2026 Jun 30. doi: 10.1111/jgh.70540.
    >> Share

  42. ULLAH W, Ashok K, Antar AS
    Comments on "Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of Hepatocellular Carcinoma Development in Patients With Chronic Hepatitis B".
    J Gastroenterol Hepatol. 2026 Jun 26. doi: 10.1111/jgh.70539.
    >> Share

  43. KHAN SA, Bharadwaj HR, Sharma A, Dhali A, et al
    Artificial Intelligence in Surveillance of Hepatocellular Carcinoma: Hype or Reality?
    J Gastroenterol Hepatol. 2026 Jun 25. doi: 10.1111/jgh.70536.
    >> Share

  44. CHEN J, Cai X
    Methodological Considerations for Sector-Based MRI Radiomics in Predicting Post-TACE Recurrence Location in Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2026 Jun 19. doi: 10.1111/jgh.70514.
    >> Share

  45. HE WZ, Lao JQ, Luo WW, Ye PH, et al
    Adjuvant Immunotherapy for Hepatocellular Carcinoma: The Need for Broader Evidence.
    J Gastroenterol Hepatol. 2026 Jun 7. doi: 10.1111/jgh.70494.
    >> Share

    May 2026
  46. SENGUL I, Sengul D
    Regarding IL-15 Plus Thymosin alpha1 Reduces Senescent Hepatic CD8+ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
    J Gastroenterol Hepatol. 2026 May 29. doi: 10.1111/jgh.70471.
    >> Share

  47. XU S
    Comment on "Evaluation of Factors Affecting Alpha Fetoprotein Levels in Patients With Hepatocellular Carcinoma in a Large Multicenter Cohort".
    J Gastroenterol Hepatol. 2026 May 29. doi: 10.1111/jgh.70470.
    >> Share

  48. MATONO T, Tada T, Hiraoka A, Hirooka M, et al
    Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.
    J Gastroenterol Hepatol. 2026 May 22. doi: 10.1111/jgh.70422.
    >> Share

  49. ZHU A, Hannah N, Bhala N, Raj A, et al
    Re-Evaluating Hepatocellular Carcinoma Diagnosis in Fontan-Associated Liver Disease: Are We Treating the Right Patients at the Right Time?
    J Gastroenterol Hepatol. 2026 May 18. doi: 10.1111/jgh.70455.
    >> Share

  50. ZHANG Z, Chen X
    Comments on "Immune Checkpoint Inhibitor-Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: A Systematic Review and meta-Analysis".
    J Gastroenterol Hepatol. 2026 May 17. doi: 10.1111/jgh.70446.
    >> Share

    April 2026
  51. TANG NSY, Tham EKJ, Syn N, Liu K, et al
    Evaluation of Factors Affecting Alpha Fetoprotein Levels in Patients With Hepatocellular Carcinoma in a Large Multicenter Cohort.
    J Gastroenterol Hepatol. 2026 Apr 30. doi: 10.1111/jgh.70386.
    >> Share

  52. CHIU HM
    Beyond the Protocol: The Vital Role of Patient Guidance in Modern Gastroenterology and Hepatology.
    J Gastroenterol Hepatol. 2026 Apr 27. doi: 10.1111/jgh.70402.
    >> Share

  53. MUHAMMAD Y, Jin Y, Luo K, Bai H, et al
    Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy-A Comprehensive Review.
    J Gastroenterol Hepatol. 2026 Apr 23. doi: 10.1111/jgh.70357.
    >> Share

  54. GAO A, Luo J, Ye X, Hu Y, et al
    Comments on "Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort".
    J Gastroenterol Hepatol. 2026 Apr 17. doi: 10.1111/jgh.70395.
    >> Share

  55. SIRAJ DS, Hollnagel F
    Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) and Risk of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB).
    J Gastroenterol Hepatol. 2026 Apr 16. doi: 10.1111/jgh.70398.
    >> Share

  56. MEHRISH FNU, Khan T, Moazzam M
    Clinical Integration of Novel Non-Invasive Biomarkers in Hepatology: Bridging Statistical Promise and Bedside Utility.
    J Gastroenterol Hepatol. 2026 Apr 9. doi: 10.1111/jgh.70390.
    >> Share

  57. SOUZA M, Amaral MJM, Moura FS, Lima LCV, et al
    Epidemiology and Clinical Characteristics of Fatty Pancreas Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review.
    J Gastroenterol Hepatol. 2026;41:1107-1115.
    >> Share

  58. WANG ZV, Boumelhem BB, Pennell T, Bachovchin WW, et al
    A Novel Fibroblast Activation Protein-Based Algorithm to Assess Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:1311-1322.
    >> Share

    March 2026
  59. JINATO T, Sikaroodia M, Gilleveta PM, Dissayabutra T, et al
    Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort.
    J Gastroenterol Hepatol. 2026 Mar 30. doi: 10.1111/jgh.70358.
    >> Share

  60. CHAN LL, Chan KOK, Chan SL
    Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard-of-Care and Emerging Therapeutic Strategies.
    J Gastroenterol Hepatol. 2026 Mar 26. doi: 10.1111/jgh.70354.
    >> Share

  61. WU F, Guo Z, Guan J, Xu J, et al
    IL-15 Plus Thymosin alpha1 Reduces Senescent Hepatic CD8(+) T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
    J Gastroenterol Hepatol. 2026 Mar 26. doi: 10.1111/jgh.70359.
    >> Share

  62. KIM MN
    Reply Letter to: A Critical Assessment of "Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis".
    J Gastroenterol Hepatol. 2026 Mar 25. doi: 10.1111/jgh.70335.
    >> Share

  63. KHAN T, Rizvi AR, Ahmad R, Saqib HW, et al
    Enhancing Prognostication in Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Beyond Baseline ALBI Grade.
    J Gastroenterol Hepatol. 2026 Mar 22. doi: 10.1111/jgh.70355.
    >> Share

  64. MIN EK, Kim SS, Ahn B, Kim DG, et al
    Diagnostic Value of MR Elastography and MRI-Proton Density Fat Fraction in Cirrhosis Based on Explant Liver Histology.
    J Gastroenterol Hepatol. 2026 Mar 13. doi: 10.1111/jgh.70316.
    >> Share

  65. AKKUS E, Yasar HA
    Immune Checkpoint Inhibitor-Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Mar 13. doi: 10.1111/jgh.70318.
    >> Share

  66. BAE SK, Akamatsu N, Ichida A, Nishioka Y, et al
    High Intrahepatic cccDNA in Resolved HBV Infection: Insights From Living Donor Liver Transplantation With Anti-HBc-Positive Grafts.
    J Gastroenterol Hepatol. 2026 Mar 11. doi: 10.1111/jgh.70324.
    >> Share

  67. ZHANG S, Wang W, Cai W, Zhong B, et al
    MR Radiomics Combined With Radiologic Features to Predict Recurrence Location in Nonviable Hepatocellular Carcinoma After Transarterial Chemoembolization.
    J Gastroenterol Hepatol. 2026 Mar 7. doi: 10.1111/jgh.70325.
    >> Share

  68. MUJAHID MUF, Haider E
    A Critical Assessment of "Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis".
    J Gastroenterol Hepatol. 2026 Mar 7. doi: 10.1111/jgh.70328.
    >> Share

  69. PARK HJ, Kim SY, Lim YS
    Updates in Abbreviated MRI-Based HCC Surveillance.
    J Gastroenterol Hepatol. 2026;41:914-926.
    >> Share

  70. HSIEH ML, Su TH, Lin YC, Chen YY, et al
    Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:1041-1051.
    >> Share

  71. LI Y, Li J, Dullaart RPF, Moshage H, et al
    Bacterial Extracellular Vesicles in the Pathogenesis and Treatment of Liver Diseases.
    J Gastroenterol Hepatol. 2026;41:880-894.
    >> Share

  72. KWON YJ, Kim M, Heo SJ, Lee JW, et al
    Combined Impact of Triglyceride-Glucose Index and Alanine Aminotransferase on Steatotic Liver Disease and Subtypes.
    J Gastroenterol Hepatol. 2026;41:1030-1040.
    >> Share

    February 2026
  73. LV E, Yao X, Jiang H
    Comment Letter: Toward Precision Medicine in Portal Hypertension: Insights From the Carvedilol Versus Propranolol Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Feb 26. doi: 10.1111/jgh.70321.
    >> Share

  74. LI X, Wu Z, He Z, Xu Y, et al
    The Impact of Hepatitis B Virus on the Tumor Microenvironment of Hepatocellular Carcinoma and Therapeutic Strategies.
    J Gastroenterol Hepatol. 2026 Feb 24. doi: 10.1111/jgh.70309.
    >> Share

  75. JIANG E, Chen Y, Chen M, Zhou Y, et al
    Oncogenic LPCAT1 Accelerates Intrahepatic Cholangiocarcinoma Development Through PI3K/Akt Signaling-Dependent Cell Cycle Regulation.
    J Gastroenterol Hepatol. 2026 Feb 19. doi: 10.1111/jgh.70291.
    >> Share

  76. JOSHI A, Raja HAA, Roy P, Latif F, et al
    Response to Letter to the Editor: Toward Precision Medicine in Portal Hypertension: Insights From the Carvedilol Versus Propranolol Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Feb 13. doi: 10.1111/jgh.70305.
    >> Share

  77. O'HARA SP, Bogert PT, Dickinson S, Chen X, et al
    Plasma Biomarkers of Senescence in Cholestatic Liver Disease: A Signature of Risk Stratification and Progression.
    J Gastroenterol Hepatol. 2026 Feb 13. doi: 10.1111/jgh.70279.
    >> Share

  78. KOGISO T, Takano S, Ogasawara Y, Taniai M, et al
    Clinical Outcomes of Fontan-Associated Hepatocellular Carcinoma: a Single-Center Retrospective Study.
    J Gastroenterol Hepatol. 2026 Feb 11. doi: 10.1111/jgh.70280.
    >> Share

  79. JANG TY
    Interaction Between Genetic Variants and Air Pollution and the Risk of Hepatocellular Carcinoma in Cirrhotic Patients.
    J Gastroenterol Hepatol. 2026 Feb 6. doi: 10.1111/jgh.70282.
    >> Share

  80. NISHIDA H
    Comment on "Helicobacter pylori Screening and Eradication in Junior High School Students in Yokosuka, Japan: Prevalence, Eradication Rates, and Challenges" (J Gastroenterol Hepatol 2025; 40:2499-2506).
    J Gastroenterol Hepatol. 2026 Feb 6. doi: 10.1111/jgh.70284.
    >> Share

  81. AHMED N, Riaz A, Ahmed BB, Noorzai R, et al
    Comment on "Role of ALBI Grade as a Predictive Factor for Long-Term Mortality in Patients With Hepatocellular Carcinoma (HCC) Undergoing Trans-Arterial Chemoembolization (TACE)".
    J Gastroenterol Hepatol. 2026 Feb 4. doi: 10.1111/jgh.70243.
    >> Share

  82. FARAH H, Kadhim-Abosaoda M, Mohaisen-Mousa H, Jyothi R, et al
    Exosome-Based Strategies in Hepatocellular Carcinoma: Mechanisms, Immunotherapy, and Clinical Challenges.
    J Gastroenterol Hepatol. 2026 Feb 2. doi: 10.1111/jgh.70245.
    >> Share

  83. PANG Y, Wang H, Ding L, Chen Y, et al
    Nomogram Predicting Survival in Gastroesophageal Variceal Bleeding Treated With Sclerotherapy and Cyanoacrylate.
    J Gastroenterol Hepatol. 2026;41:705-719.
    >> Share

  84. TANG S, Xie W, Wu Z, Yang J, et al
    LETIM Robustly Predicts Immune Checkpoint Blockade Efficacy for Liver Cancer Patients Using Multiple Immune-Related Genesets.
    J Gastroenterol Hepatol. 2026;41:763-773.
    >> Share

  85. DENG X, Huang N, Du K, Zhang H, et al
    The Spleen Promotes Liver Sinusoidal Endothelial Cell Angiogenesis by Stimulating the TGFbeta/Smad2/3 Pathway Through GDF15.
    J Gastroenterol Hepatol. 2026;41:774-786.
    >> Share

  86. GONZALEZ-GARCIA K, Zertuche-Martinez C, Reyes-Avendano I, Reyes-Jimenez E, et al
    An Integrated Systematic Review and Meta-Analysis From the Bloodstream to Identify Potential Biomarkers for ALD, MASLD, and HCC Without a Viral Background.
    J Gastroenterol Hepatol. 2026;41:502-515.
    >> Share

  87. KRISHNAN A, Kadakia KC, Rudnick SR, deLemos AS, et al
    Modern Diets, Metabolic Inequity, and Race-Ethnic Disparities: Unraveling the Associations With MASLD and Cancer Risk.
    J Gastroenterol Hepatol. 2026;41:573-585.
    >> Share

  88. FAN JB, Qin LQ, Ding L, Zhang L, et al
    Effects of Piperine on Obese and Lean Nonalcoholic Fatty Liver Disease in Mice.
    J Gastroenterol Hepatol. 2026;41:753-762.
    >> Share

  89. MOHAMMADPOUR Z, Castrejon Moreno M, Moazzami B, Mudaliar S, et al
    Endoscopic Ultrasound-Guided Coiling Plus Glue Injection Compared With Other Endoscopic Modalities in Managing Gastric Varices: A Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2026;41:413-428.
    >> Share

    January 2026
  90. KO KA, Sohn W
    Response to the Letter on "Role of ALBI Grade as a Predictive Factor for Long-Term Mortality in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)".
    J Gastroenterol Hepatol. 2026 Jan 15. doi: 10.1111/jgh.70246.
    >> Share

  91. INOUE T, Kitano R, Kitada T, Sakamoto K, et al
    Endoscopic Ultrasound-Guided Bilateral Stent-in-Stent Deployment With Hepaticoenterostomy in patients With Malignant Hilar Biliary Obstruction.
    J Gastroenterol Hepatol. 2026 Jan 15. doi: 10.1111/jgh.70236.
    >> Share

  92. XU J, Ma H, Yang W, Tu R, et al
    ATF3 Mediates the Immunoregulatory Role of the Tim-3 Pathway in Primary Biliary Cholangitis.
    J Gastroenterol Hepatol. 2026 Jan 15. doi: 10.1111/jgh.70234.
    >> Share

  93. AL-KHREISAT MJ, Kadhim-Abosaoda M, Abas Ibrahim N, Malathi H M, et al
    Circulating Tumor Cells as Diagnostic and Therapeutic Biomarkers in Hepatocellular Carcinoma: Advancing Precision Oncology Through Liquid Biopsy.
    J Gastroenterol Hepatol. 2026 Jan 5. doi: 10.1111/jgh.70197.
    >> Share

  94. LIM AH, Litwin PS, Dionela W, Tse E, et al
    Endoscopic Ultrasound Guided Portal Pressure Gradient Measurement in Predicting Outcomes of Abdominal Surgery in Patients With Chronic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:286-292.
    >> Share

  95. HUANG YC, Wang CW, Huang JC, Liang PC, et al
    FIB-4 Serves as a Referral Index for Coronary Artery Calcification in Patients With MASLD.
    J Gastroenterol Hepatol. 2026;41:332-340.
    >> Share

    December 2025
  96. DIRJAYANTO VJ, Yiu DSM, Chen R, Fan KH, et al
    Nutrition in Hepatocellular Carcinoma: Pathophysiological Insights, Impact, and Implications for Clinical Practice.
    J Gastroenterol Hepatol. 2025 Dec 12. doi: 10.1111/jgh.70186.
    >> Share

  97. LIU Z, Jiang H, Li F, Xie R, et al
    Bile Acid Metabolites Control Th17/Treg Balance in Primary Biliary Cholangitis: Mechanisms of Disease Progression and Therapeutic Targets.
    J Gastroenterol Hepatol. 2025 Dec 7. doi: 10.1111/jgh.70189.
    >> Share

  98. SO JE, Jeong J, Hong JP, Kim DY, et al
    The Impact of Liraglutide on Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2025;40:2976-2986.
    >> Share

  99. SATO S, Kawai H, Yamaguchi M, Nago H, et al
    Fibrosis in Asymptomatic Steatotic Liver Disease With Normal Alanine Aminotransferase: Analysis of 2448 Health Check-Up Cohort by Ultrasound Attenuation Imaging and Shear Wave Elastography.
    J Gastroenterol Hepatol. 2025;40:2987-2996.
    >> Share

  100. AL-HUNEIDI LI, Zhao F, Maas R, Ermans SJE, et al
    Liver Fat Quantification and Steatosis Grading in Fatty Liver Disease by Magnetic Resonance Imaging: Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2025;40:2808-2819.
    >> Share

  101. JAMES M, Smuk M, Rahman N, Black G, et al
    Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease in South Asian Ethnicities: A Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2025;40:2830-2841.
    >> Share

    November 2025
  102. CHEN YC, Chang YP, Lee JY, Chen CY, et al
    Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2025 Nov 14. doi: 10.1111/jgh.70160.
    >> Share

  103. ITO T, Shimose S, Saeki I, Takeuchi Y, et al
    Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2025 Nov 14. doi: 10.1111/jgh.70150.
    >> Share

  104. LIAO KF, Lai SW
    Aspirin Use and Hepatocellular Carcinoma Risk.
    J Gastroenterol Hepatol. 2025 Nov 6. doi: 10.1111/jgh.70168.
    >> Share

  105. XIE W
    Letter: A Deep Dive and Future Outlook on the Study of Hypertension's Impact on the Efficacy of Atezolizumab Plus Bevacizumab in Treating Unresectable Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2025 Nov 5. doi: 10.1111/jgh.70154.
    >> Share

  106. LIU L, Xia Y, Wang B, Zhang Y, et al
    Efficacy of Incretin-Based Therapies in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Gastroenterol Hepatol. 2025;40:2659-2673.
    >> Share

    October 2025
  107. FAN C, He X, Zhou Y, Ye C, et al
    The Effects of CD100 Stimulation on Primary Human Hepatocytes (PHHs) and Its Implications in HBV-Related Liver Cirrhosis.
    J Gastroenterol Hepatol. 2025 Oct 21. doi: 10.1111/jgh.70123.
    >> Share

  108. AGARWAL A, Pachisia AV, Agarwal S, Mehta S, et al
    Celiac Disease and Its Impact on Liver-Related Outcomes in Patients With All-Cause Cirrhosis: The CELIHEP Study.
    J Gastroenterol Hepatol. 2025 Oct 16. doi: 10.1111/jgh.70082.
    >> Share

  109. XU L, Liu J
    Comment on Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of Real-World Evidence.
    J Gastroenterol Hepatol. 2025 Oct 16. doi: 10.1111/jgh.70114.
    >> Share

  110. KO KA, Oh H, Kim MS, Hong HP, et al
    Role of ALBI Grade as a Predictive Factor for Long-Term Mortality in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    J Gastroenterol Hepatol. 2025 Oct 3. doi: 10.1111/jgh.70098.
    >> Share

  111. ZENG X, Li Z, Chen Y, Yao H, et al
    Impairing Islets in Newborn Mice Promotes Liver Fibrosis and Carcinoma Development in a Rapid NASH Model.
    J Gastroenterol Hepatol. 2025;40:2601-2612.
    >> Share

  112. VIJAYALEKSHMI B, Chaudhary A, Prabhu SB, Sharma A, et al
    Plasma-Driven Monocyte Dysfunction Drives Disease Progression in Alcohol-Related Acute-on-Chronic Liver Failure.
    J Gastroenterol Hepatol. 2025;40:2591-2600.
    >> Share

  113. KIM MN, Park GU, You SC, Lee JS, et al
    Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis.
    J Gastroenterol Hepatol. 2025 Oct 1. doi: 10.1111/jgh.70078.
    >> Share

    September 2025
  114. ABREU ES, Fernandes GP, Lacerda HC, Reginato PH, et al
    Efficacy and Safety of Obeticholic Acid as Second-Line Therapy in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2025 Sep 30. doi: 10.1111/jgh.70094.
    >> Share

  115. MAESAKA K, Hikita H, Kai M, Tahata Y, et al
    Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2025 Sep 9. doi: 10.1111/jgh.70068.
    >> Share

  116. ZHANG Y, Jiang L, Jiang Y, Zhu L, et al
    Elevated HSP70 Ameliorates Liver Failure Patients via Its Novel Natural Inhibitor.
    J Gastroenterol Hepatol. 2025;40:2300-2310.
    >> Share

  117. KUO CH, El-Omar E, Kao CY, Lin JT, et al
    Compositional and Metabolomic Shifts of the Gut Microbiome in Alcohol-Related Liver Disease.
    J Gastroenterol Hepatol. 2025;40:2176-2189.
    >> Share

  118. EZHILARASAN D
    Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
    J Gastroenterol Hepatol. 2025;40:2163-2175.
    >> Share

    August 2025
  119. KARATAYLI SC, Weber SN, Hall RA, Hohl M, et al
    Hepatic Inflammation and Liver Injury in a Model of Bacterial Infection Triggered Acute-on-Chronic Liver Injury.
    J Gastroenterol Hepatol. 2025 Aug 17. doi: 10.1111/jgh.70055.
    >> Share

  120. HEGAZY RA
    Unraveling Liver Cirrhosis: Bridging Pathophysiology to Innovative Therapeutics.
    J Gastroenterol Hepatol. 2025 Aug 3. doi: 10.1111/jgh.70037.
    >> Share

  121. CHEN YX, Wu YP, Zhang Y, Ji PX, et al
    Modulation of Lipid Metabolism and Keap1-Nrf2 Pathway Activation in Macrophages by Targeting PPARgamma Affects NAFLD Progression.
    J Gastroenterol Hepatol. 2025;40:2119-2133.
    >> Share

  122. DANPANICHKUL P, Thongprayoon C, Suparan K, Kim D, et al
    Evolving Public Attention to Steatotic Liver Disease: A 20-Year Analysis (2004-2024): Surging Steatotic Liver Disease Focus.
    J Gastroenterol Hepatol. 2025;40:2053-2059.
    >> Share

  123. LIU Z, Liu L, Liu S, Ba Y, et al
    Genome-Scale CRISPR-Cas9 Analysis Reveals Tumor Heterogeneity and Identifies NDC80 as Novel Biomarker in HCC.
    J Gastroenterol Hepatol. 2025;40:2078-2090.
    >> Share

  124. HATANAKA T, Kakizaki S, Hiraoka A, Tada T, et al
    Comparison of Surgical Resection and Radiofrequency Ablation for Early-Stage HCC Patients With Child-Pugh Class B.
    J Gastroenterol Hepatol. 2025;40:2068-2077.
    >> Share

  125. GHANI L, Aboona MB, Faulkner CS, Rangan P, et al
    Increased Mortality Among Lean Versus Non-Lean Adults With MASLD: A Multicenter Study.
    J Gastroenterol Hepatol. 2025;40:1919-1925.
    >> Share

    July 2025
  126. CHEN Y, Zhai D, Shen J, Hu W, et al
    Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of Real-World Evidence.
    J Gastroenterol Hepatol. 2025 Jul 26. doi: 10.1111/jgh.70003.
    >> Share

  127. LIU C, Chen G, Liao J, Wu D, et al
    m6A Modification-Mediated Regulation of DCAF13 Promotes Glycolytic Metabolism and Drives Hepatocellular Carcinoma Progression via Interaction With G6PD.
    J Gastroenterol Hepatol. 2025 Jul 25. doi: 10.1111/jgh.70015.
    >> Share

  128. JANG TY, Wang CW, Liang PC, Wei YJ, et al
    Steatotic Liver Disease-Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog-Treated Chronic Hepatitis B.
    J Gastroenterol Hepatol. 2025 Jul 24. doi: 10.1111/jgh.70021.
    >> Share

  129. KIM YJ, Kim JW
    HDAC9 as a Sex-Dependent Epigenetic Driver of Hepatic Steatosis and Adipose Inflammation.
    J Gastroenterol Hepatol. 2025 Jul 24. doi: 10.1111/jgh.70029.
    >> Share

  130. SUN R, Wang X, Ma J, Cai Y, et al
    The Roles and Clinical Significance of Major Hepatic-Derived Metabolites in Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2025 Jul 19. doi: 10.1111/jgh.70008.
    >> Share

    June 2025
  131. CAINES A, Lu M, Wu T, Trudeau S, et al
    Pre-Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis.
    J Gastroenterol Hepatol. 2025 Jun 23. doi: 10.1111/jgh.17035.
    >> Share

  132. WANG L, Zhao Y, Duan B, Wang Y, et al
    Iron Quantification Using Spectral CT-Based Material Decomposition Technique for Noninvasive Hepatic Fibrosis Staging: An Experimental Study.
    J Gastroenterol Hepatol. 2025 Jun 4. doi: 10.1111/jgh.17031.
    >> Share

  133. GUO X, Wu L, Lai J, Wu Y, et al
    Causal Associations Between Lipids, NPC1L1, and Liver Cancer Risk: Insights From Mendelian Randomization and Bioinformatics.
    J Gastroenterol Hepatol. 2025;40:1602-1615.
    >> Share

  134. XIA Y, Tie J, Wang G, Wu H, et al
    Benefits of TIPS for Patients With Large Ascites Preceding Recurrent or Refractory ascites: A Multicenter Cohort Study.
    J Gastroenterol Hepatol. 2025;40:1574-1585.
    >> Share

    May 2025
  135. NIIZEKI T, Mawatari S, Shibata M, Sasaki R, et al
    Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First-Line Therapy for Intermediate-Stage Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria.
    J Gastroenterol Hepatol. 2025 May 31. doi: 10.1111/jgh.17024.
    >> Share

  136. WANG J, Gao J, Zhang Q, Lu J, et al
    Ileal FXR Knockdown Ameliorates MASLD Progression in Rats via Modulating Bile Acid Metabolism Mediated by Gut Microbiota.
    J Gastroenterol Hepatol. 2025 May 24. doi: 10.1111/jgh.17017.
    >> Share

  137. MATSUBARA Y, Tsuboi A, Shigenobu S, Hirata I, et al
    Clinical Significance of Small-Bowel Mucosal Changes in Liver Cirrhosis Patients With Suspected Small-Bowel Bleeding: A Capsule Endoscopy Study.
    J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.17002.
    >> Share

  138. JOSHI A, Raja HAA, Roy P, Latif F, et al
    Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure Gradient in Liver Cirrhosis: A Meta-Analysis.
    J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.16999.
    >> Share

  139. QIN J, Zhu W, Zhou W
    Navigating the Paradox of IL-22: Friend or Foe in Hepatic Health?
    J Gastroenterol Hepatol. 2025 May 13. doi: 10.1111/jgh.16991.
    >> Share

  140. LIOU WL, Tan SY, Yamada H, Krishnamoorthy T, et al
    Performance of the GALAD Model in an Asian Cohort Undergoing Hepatocellular Carcinoma Surveillance: A Prospective Cohort Study.
    J Gastroenterol Hepatol. 2025 May 10. doi: 10.1111/jgh.16997.
    >> Share

  141. DONG L, Zhang H, Kang Y, Wang F, et al
    NLRP3 and Gut-Liver Axis: New Possibility for the Treatment of Alcohol-Associated Liver Disease.
    J Gastroenterol Hepatol. 2025;40:1070-1078.
    >> Share

  142. FUKAMIZO K, Hagiwara Y, Kimura T, Matsuyama Y, et al
    Individualized Effects of Weight Gain in Adulthood on the Development of MASLD in Japanese Non-Obese Individuals.
    J Gastroenterol Hepatol. 2025;40:1255-1262.
    >> Share

  143. CHANG YW, Kuo CN, Chang CL, Hsu JC, et al
    Sequential Treatment of Metastatic Colorectal Cancer in Taiwan: Real-World Evidence From Regorafenib and Trifluridine/Tipiracil Use.
    J Gastroenterol Hepatol. 2025;40:1135-1142.
    >> Share

    April 2025
  144. TAMAKI N, Huang DQ, Lee HW, Park SY, et al
    Head-to-Head Comparison of Long-Term HCC Risk of Antivirals-Treated Versus Untreated Low-Level Viremia in HBV-Compensated Cirrhosis.
    J Gastroenterol Hepatol. 2025 Apr 27. doi: 10.1111/jgh.16986.
    >> Share

  145. LEE HA, Lee HW, Seo YS, Sinn DH, et al
    Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy-Induced HBsAg Seroclearance.
    J Gastroenterol Hepatol. 2025 Apr 24. doi: 10.1111/jgh.16973.
    >> Share


  146. Correction to "PLK2 Inhibited Oxidative Stress and Ameliorated Hepatic Ischemia-Reperfusion Injury Through Phosphorylating GSK3beta".
    J Gastroenterol Hepatol. 2025 Apr 10. doi: 10.1111/jgh.16966.
    >> Share

  147. FILHO VOC, Passos PRC
    PCED1A as a Predictive Biomarker for Immunotherapy and Anti-Angiogenic Treatment in Hepatocellular and Colorectal Cancer.
    J Gastroenterol Hepatol. 2025 Apr 9. doi: 10.1111/jgh.16969.
    >> Share

  148. LI J, Zhao Y, Wang Z, Ma A, et al
    Irisin Alleviates Impaired Mitochondrial Fusion via Enhancing PKA/SIRT3/mTOR Pathway in Hepatic Steatosis.
    J Gastroenterol Hepatol. 2025 Apr 2. doi: 10.1111/jgh.16950.
    >> Share

  149. PARK SH, Song SJ, Lee JA, Shin JA, et al
    Effects of Aging on the Severity of Liver Injury in Mice With Iron Overload.
    J Gastroenterol Hepatol. 2025;40:1016-1025.
    >> Share

  150. MATONO T, Tada T, Kumada T, Hiraoka A, et al
    Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC.
    J Gastroenterol Hepatol. 2025;40:949-959.
    >> Share

  151. ZHAO N, Wang H, Zhang M, Tian W, et al
    Characterization of NK Cells Using Single-Cell RNA Sequencing in Patients With Acute-On-Chronic Liver Failure.
    J Gastroenterol Hepatol. 2025;40:917-929.
    >> Share

  152. ZHAI X, He X, Huang A, Liu Z, et al
    Analysis of Immunometabolic Profiles in Patients With Chronic Drug-Induced Liver Injury and Validation in Mice to Reveal Potential Mechanisms.
    J Gastroenterol Hepatol. 2025;40:987-1003.
    >> Share

    March 2025

  153. Correction to 'Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance'.
    J Gastroenterol Hepatol. 2025 Mar 14. doi: 10.1111/jgh.16918.
    >> Share

  154. TAO Q, Zhou Y, Chen G, Sun J, et al
    Cisplatin Promotes Hepatotoxicity by cGAS-STING Mediated Innate Immune Response.
    J Gastroenterol Hepatol. 2025 Mar 7. doi: 10.1111/jgh.16926.
    >> Share

  155. JAFARI-KHORCHANI M, Pantopoulos K, Zare-Mehrjardi MJ, Allameh A, et al
    Sequential Changes in NOX4 Expression, Oxidative Stress Indices, PIIINP, and Liver Histopathology During Hepatocellular Carcinogenesis Induced in Mice.
    J Gastroenterol Hepatol. 2025 Mar 3. doi: 10.1111/jgh.16914.
    >> Share

    February 2025
  156. GIRI S, Ingawale S, Khatana G, Gore P, et al
    Metabolic Cause of Cirrhosis Is the Emerging Etiology for Primary Liver Cancer in the Asia-Oceania Region: Analysis of Global Burden of Disease (GBD) Study 2021.
    J Gastroenterol Hepatol. 2025 Feb 27. doi: 10.1111/jgh.16922.
    >> Share

  157. LIAO C, Zhang Y, Yang J, Wang S, et al
    Single-Cell Transcriptomic Analysis Reveals an Aggressive Basal-Like Tumor Cell Subpopulation Associated With Poor Prognosis in Intrahepatic Cholangiocarcinoma.
    J Gastroenterol Hepatol. 2025 Feb 24. doi: 10.1111/jgh.16915.
    >> Share

  158. EZHILARASAN D
    Thyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom.
    J Gastroenterol Hepatol. 2025;40:367-378.
    >> Share

  159. SINGH SP, Bhatia V, Kale P, Kumar G, et al
    Bowel Colonization With Carbapenem-Resistant Bacteria Is Associated With Short-Term Outcomes in Patients With Acute-On-Chronic Liver Failure.
    J Gastroenterol Hepatol. 2025;40:528-536.
    >> Share

    January 2025
  160. ANG TL, Hang DV, Li JW, Ho JCL, et al
    APAGE Position Statements on Green and Sustainability in Gastroenterology, Hepatology, and Gastrointestinal Endoscopy.
    J Gastroenterol Hepatol. 2025 Jan 31. doi: 10.1111/jgh.16896.
    >> Share

  161. PENG J, Zhang L, Dong Y, Long W, et al
    Factors Influencing Liver Cirrhosis Progression in Wilson's Disease Patients: A Retrospective Cohort Study Over 5 Years.
    J Gastroenterol Hepatol. 2025 Jan 31. doi: 10.1111/jgh.16889.
    >> Share

  162. SONG BG, Park G, Goh MJ, Kang W, et al
    A Risk Prediction Model for Hepatocellular Carcinoma in the General Population Without Traditional Risk Factors for Liver Disease.
    J Gastroenterol Hepatol. 2025 Jan 29. doi: 10.1111/jgh.16893.
    >> Share

  163. SHIN SK, Mishima Y, Lee Y, Kwon OS, et al
    Current Landscape of Adoptive Cell Therapy and Challenge to Develop "Off-The-Shelf" Therapy for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2025 Jan 26. doi: 10.1111/jgh.16872.
    >> Share

  164. WANG M, Zhang Q, Wang J
    Expression of PCED1A in Hepatocellular Carcinoma and Colorectal Cancer and Its Relationship with Immune Infiltration: Potential as a Diagnostic Marker.
    J Gastroenterol Hepatol. 2025 Jan 26. doi: 10.1111/jgh.16890.
    >> Share

  165. REN X, Wu Y, Song T, Yang Q, et al
    Clonorchis sinensis Promotes Intrahepatic Cholangiocarcinoma Progression by Activating FASN-Mediated Fatty Acid Metabolism.
    J Gastroenterol Hepatol. 2025 Jan 13. doi: 10.1111/jgh.16879.
    >> Share

  166. ZHAO Y, Zhu W, Dong S, Zhang H, et al
    Glucose Metabolism Reprogramming of Immune Cells in the Microenvironment of Pancreatic and Hepatobiliary Cancers.
    J Gastroenterol Hepatol. 2025 Jan 8. doi: 10.1111/jgh.16873.
    >> Share

  167. HATANAKA T, Kakizaki S, Hiraoka A, Tada T, et al
    Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models.
    J Gastroenterol Hepatol. 2025 Jan 6. doi: 10.1111/jgh.16871.
    >> Share

  168. KIM A, Kang D, Choi SC, Sinn DH, et al
    Cardiometabolic risk factors and coronary atherosclerosis progression in patients with metabolic dysfunction-associated steatotic liver disease: the influential role of quantity over type.
    J Gastroenterol Hepatol. 2025;40:258-264.
    >> Share

  169. GUPTA P, Hsu YC, Liang LL, Chu YC, et al
    Automatic localization and deep convolutional generative adversarial network-based classification of focal liver lesions in computed tomography images: A preliminary study.
    J Gastroenterol Hepatol. 2025;40:166-176.
    >> Share

  170. TAMURA Y, Saeki C, Kanai T, Kiryu S, et al
    Comparison of the ability between dual-energy X-ray absorptiometry and bioelectrical impedance analysis for diagnosing low skeletal muscle mass and sarcopenia in patients with chronic liver disease.
    J Gastroenterol Hepatol. 2025;40:274-281.
    >> Share

  171. VAZ K, Kemp W, Majeed A, Lubel J, et al
    Validation of serum non-invasive tests of liver fibrosis as prognostic markers of clinical outcomes in people with fatty liver disease in Australia.
    J Gastroenterol Hepatol. 2025;40:241-249.
    >> Share

  172. CUI XS, Li HZ, Li L, Xie CZ, et al
    Rodent model of metabolic dysfunction-associated fatty liver disease: a systematic review.
    J Gastroenterol Hepatol. 2025;40:48-66.
    >> Share

    December 2024
  173. HU S, Kang H, Bae M, Kim MB, et al
    Histone Deacetylase 9 Deletion Inhibits Hepatic Steatosis and Adipose Tissue Inflammation in Male Diet-Induced Obese Mice.
    J Gastroenterol Hepatol. 2024 Dec 27. doi: 10.1111/jgh.16856.
    >> Share

  174. KOH HH, Kang M, Kim DG, Park JH, et al
    Comparative Validation of Prediction Models for HCC Outcomes in Living Donor Liver Transplantation: Superiority of Tumor Markers to Imaging Study.
    J Gastroenterol Hepatol. 2024 Dec 26. doi: 10.1111/jgh.16857.
    >> Share

  175. SALEEPOL A, Chulroek T, Vimonsuntirungsri T, Luangsukrerk T, et al
    Gastrointestinal: Direct Visualization of Biliary Tuberculosis.
    J Gastroenterol Hepatol. 2024 Dec 11. doi: 10.1111/jgh.16836.
    >> Share

  176. CHEN J, Chen X, Cai H, Yang Y, et al
    The ubiquitination degradation of KLF15 mediated by WSB2 promotes lipogenesis and progression of hepatocellular carcinoma via inhibiting PDLIM2 expression.
    J Gastroenterol Hepatol. 2024 Dec 5. doi: 10.1111/jgh.16812.
    >> Share

  177. WONG DN, Hui RW, Mak LY, Seto WK, et al
    Gastrointestinal: Biliary Obstruction From Hepatic Artery Aneurysms: Implications for Treatment Selection.
    J Gastroenterol Hepatol. 2024 Dec 4. doi: 10.1111/jgh.16841.
    >> Share

  178. NIKOLI A, Orfanidou M, Goulas A, Goulis DG, et al
    Circulating lipoprotein(a) in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:2572-2581.
    >> Share

  179. MALANDRIS K, Arampidis D, Mainou M, Papadopoulos N, et al
    FibroScan-AST score for diagnosing fibrotic MASH: A systematic review and meta-analysis of diagnostic test accuracy studies.
    J Gastroenterol Hepatol. 2024;39:2582-2591.
    >> Share

  180. PAN L, Wang L, Ma H, Ding F, et al
    Relevance of combined influence of nutritional and inflammatory status on non-alcoholic fatty liver disease and advanced fibrosis: A mediation analysis of lipid biomarkers.
    J Gastroenterol Hepatol. 2024;39:2853-2862.
    >> Share

  181. US ALTAY D, Kaya Y, Mataraci Degirmenci D, Kocyigit E, et al
    Non-alcoholic fatty liver disease: The importance of physical activity and nutrition education-A randomized controlled study.
    J Gastroenterol Hepatol. 2024;39:2723-2734.
    >> Share

  182. TENG X, Shang J, Du L, Huang W, et al
    RNA-binding protein Trx regulates alternative splicing and promotes metastasis of HCC via interacting with LINC00152.
    J Gastroenterol Hepatol. 2024;39:2892-2902.
    >> Share

  183. KIM K, Lee Y, Lee JS, Kim MN, et al
    Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study.
    J Gastroenterol Hepatol. 2024;39:2845-2852.
    >> Share

  184. MORISHIMA S, Abe A, Okamoto S, Kapoor MP, et al
    Partially hydrolyzed guar gum suppresses binge alcohol-induced liver fat accumulation via gut environment modulation in mice.
    J Gastroenterol Hepatol. 2024;39:2700-2708.
    >> Share

  185. SUN F, Wang J, Ji X, Wang Z, et al
    CCL25 contributes to the pathogenesis of D-Gal/LPS-induced acute liver failure.
    J Gastroenterol Hepatol. 2024;39:2880-2891.
    >> Share

  186. CHEE NM, Sinnanaidu RP, Chan WK
    Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:2545-2554.
    >> Share

  187. LI Y, Dai C, Yang H, Zeng H, et al
    Cross-sectional and Mendelian randomization study of fibroblast growth factor 19 reveals causal associations with metabolic diseases.
    J Gastroenterol Hepatol. 2024;39:2872-2879.
    >> Share

    November 2024
  188. GE W, Wang Z, Zhong X, Chen Y, et al
    PLK2 inhibited oxidative stress and ameliorated hepatic ischemia-reperfusion injury through phosphorylating GSK3beta.
    J Gastroenterol Hepatol. 2024 Nov 19. doi: 10.1111/jgh.16815.
    >> Share

  189. JAROENLAPNOPPARAT A, Prasitsumrit V, Ponvilawan B, Waitayangkoon P, et al
    Clostridioides difficile infection increases in-hospital mortality, length of stay, and hospital cost but not 30-day mortality in cirrhotic patients.
    J Gastroenterol Hepatol. 2024 Nov 13. doi: 10.1111/jgh.16807.
    >> Share

  190. ZENG X, Liao Y, Cheng W
    Transient receptor potential channel 6 knockout ameliorates hepatic fibrosis by inhibiting the activation and proliferation of hepatic stellate cells.
    J Gastroenterol Hepatol. 2024 Nov 7. doi: 10.1111/jgh.16802.
    >> Share

  191. ABOONA MB, Danpanichkul P, Chen VL, Rangan P, et al
    Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake.
    J Gastroenterol Hepatol. 2024;39:2456-2463.
    >> Share

  192. LAM LK, Tan JT, Ooi PH, Zhang R, et al
    Effect of metabolic dysfunction-associated steatotic liver disease on BNT162b2 immunogenicity against the severe acute respiratory syndrome coronavirus 2 omicron variant.
    J Gastroenterol Hepatol. 2024;39:2386-2393.
    >> Share

  193. WONGTRAKUL W, Niltwat S, Charatcharoenwitthaya N, Karaketklang K, et al
    Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:2299-2307.
    >> Share

    October 2024
  194. ZHU W, Fan C, Liu B, Qin J, et al
    Therapeutic targets for hepatocellular carcinoma identified using proteomics and Mendelian randomization.
    J Gastroenterol Hepatol. 2024 Oct 30. doi: 10.1111/jgh.16785.
    >> Share

  195. PRINCE DS, Hoque S, Kim C, Maher S, et al
    Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance.
    J Gastroenterol Hepatol. 2024 Oct 24. doi: 10.1111/jgh.16782.
    >> Share

  196. LI Y, Chen L, Li S, Song H, et al
    The m6A reader IGF2BP1 contributes to the activation of hepatic stellate cells through facilitating TUBB4B mRNA stabilization.
    J Gastroenterol Hepatol. 2024 Oct 15. doi: 10.1111/jgh.16765.
    >> Share

  197. ZHANG L, Xu L, Rong A, Cui Y, et al
    Effect of Rab18 on liver injury and lipid accumulation by regulating perilipin 2 and peroxisome proliferator-activated receptor gamma in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:2219-2227.
    >> Share

  198. LEOW YW, Chan WL, Lai LL, Mustapha NRN, et al
    LIVERSTAT for risk stratification for patients with metabolic dysfunction-associated fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:2182-2189.
    >> Share

  199. YANG J, Choi WM, Lee D, Shim JH, et al
    Revisiting the steatosis-associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability.
    J Gastroenterol Hepatol. 2024;39:2112-2119.
    >> Share

  200. ALATAS FS, Yamaza T, Matsuura T, Ongko L, et al
    Potential role of stem cells from human exfoliated deciduous teeth in inducing liver regeneration.
    J Gastroenterol Hepatol. 2024;39:2190-2196.
    >> Share

    September 2024
  201. KU JL, Hsu JR, Li YT, Wu LL, et al
    Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction-associated steatotic liver disease: a comprehensive review.
    J Gastroenterol Hepatol. 2024 Sep 29. doi: 10.1111/jgh.16750.
    >> Share

  202. PASSOS PRC, Filho VOC, Noronha MM, Hyppolito EB, et al
    Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Sep 25. doi: 10.1111/jgh.16752.
    >> Share

  203. HO CT, Tan EH, Lee PC, Su CW, et al
    Reply to "Association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy: concerns to be addressed".
    J Gastroenterol Hepatol. 2024 Sep 19. doi: 10.1111/jgh.16754.
    >> Share

  204. EADIE L, Lo LA, Boivin M, Deol JK, et al
    Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review.
    J Gastroenterol Hepatol. 2024 Sep 3. doi: 10.1111/jgh.16730.
    >> Share

  205. NJEI B, Al-Ajlouni YA, Ameyaw P, Njei LP, et al
    Role of ammonia and glutamine in the pathogenesis and progression of metabolic dysfunction-associated steatotic liver disease: A systematic review.
    J Gastroenterol Hepatol. 2024;39:1788-1808.
    >> Share

  206. KIM D, Manikat R, Wijarnpreecha K, Cholankeril G, et al
    Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality.
    J Gastroenterol Hepatol. 2024;39:1950-1956.
    >> Share

  207. CHEN YT, Chen TI, Yin SC, Huang CW, et al
    Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease.
    J Gastroenterol Hepatol. 2024;39:1939-1949.
    >> Share

    August 2024
  208. HENRY-BLAKE C, Balachandrakumar V, Kassab M, Devonport J, et al
    Lower hepatocellular carcinoma surveillance in metabolic dysfunction-associated steatotic liver disease: Impact on treatment eligibility.
    J Gastroenterol Hepatol. 2024 Aug 27. doi: 10.1111/jgh.16727.
    >> Share

  209. ZHANG X, Chen C, Wang Y, Xu J, et al
    Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation.
    J Gastroenterol Hepatol. 2024 Aug 7. doi: 10.1111/jgh.16693.
    >> Share

  210. WU T, Ye J, Mo S, Ye M, et al
    Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    J Gastroenterol Hepatol. 2024;39:1636-1647.
    >> Share

  211. BANERJEE A, Blinston D, Narain MA
    Inhibition of liver fibrosis by TET1 may be B cell mediated: Supporting evidence from a case of TNFAIP3 deficiency.
    J Gastroenterol Hepatol. 2024;39:1706-1707.
    >> Share

  212. FUKUNISHI Y, Hiraoka A, Tada F, Fukumoto M, et al
    Changes in characteristics of gastroenterology center inpatients in Japan because of rapidly aging society.
    J Gastroenterol Hepatol. 2024;39:1528-1534.
    >> Share

    July 2024
  213. BIAN J, Sang X
    Association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy: Concerns to be addressed.
    J Gastroenterol Hepatol. 2024 Jul 25. doi: 10.1111/jgh.16694.
    >> Share

  214. CHU CS, Chen HP, Lin PH, Cheng CC, et al
    Interleukin-1 receptor 1 deficiency worsens hepatocellular carcinoma, while gemcitabine treatment alleviates the hepatocellular carcinoma-induced increase in intra-hepatic immune cells.
    J Gastroenterol Hepatol. 2024 Jul 15. doi: 10.1111/jgh.16674.
    >> Share

  215. XIN Z, Chen H, Xu J, Zhang H, et al
    Exosomal mRNA in plasma serves as a predictive marker for microvascular invasion in hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Jul 7. doi: 10.1111/jgh.16677.
    >> Share

  216. NAKASHIMA R, Kitano Y, Okabe H, Tanizaki T, et al
    Rising pseudocysts in the hepatoduodenal ligament caused by a ruptured intraductal papillary mucinous neoplasm with surgical treatment.
    J Gastroenterol Hepatol. 2024 Jul 1. doi: 10.1111/jgh.16669.
    >> Share

  217. MORI K, Akiyama Y, Tanaka M, Sato T, et al
    Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
    J Gastroenterol Hepatol. 2024;39:1382-1393.
    >> Share

  218. MALANDRIS K, Papandreou S, Vasilakou D, Kakotrichi P, et al
    Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis.
    J Gastroenterol Hepatol. 2024;39:1219-1229.
    >> Share

  219. LEE RC, Liang PC, Liang HL, Chen YF, et al
    Multicenter evaluation of the safety and efficacy of selective internal radiation therapy with yttrium-90 resin microspheres in Taiwan: data from the RESIN registry.
    J Gastroenterol Hepatol. 2024;39:1318-1327.
    >> Share

  220. SUGITA H, Nakanuma S, Munesue S, Ishikawa T, et al
    Cilostazol improves the prognosis after hepatectomy in rats with sinusoidal obstruction syndrome.
    J Gastroenterol Hepatol. 2024;39:1413-1421.
    >> Share

    June 2024
  221. SUZUKI T, Matsuura K, Suzuki Y, Okumura F, et al
    Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.
    J Gastroenterol Hepatol. 2024 Jun 28. doi: 10.1111/jgh.16672.
    >> Share

  222. CHENG J, Yang S, Shou D, Chen J, et al
    FOXO1 induced fatty acid oxidation in hepatic cells by targeting ALDH1L2.
    J Gastroenterol Hepatol. 2024 Jun 25. doi: 10.1111/jgh.16662.
    >> Share

  223. CHATZIPANAGIOTOU OP, Loukas C, Vailas M, Machairas N, et al
    Artificial intelligence in hepatocellular carcinoma diagnosis: a comprehensive review of current literature.
    J Gastroenterol Hepatol. 2024 Jun 23. doi: 10.1111/jgh.16663.
    >> Share

  224. MAUNG ST, Tanpowpong N, Satja M, Treeprasertsuk S, et al
    MRI for hepatocellular carcinoma and the role of abbreviated MRI for surveillance of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Jun 20. doi: 10.1111/jgh.16643.
    >> Share

  225. MALIK S, Tenorio BG, Moond V, Dahiya DS, et al
    Systematic review of machine learning models in predicting the risk of bleed/grade of esophageal varices in patients with liver cirrhosis: A comprehensive methodological analysis.
    J Gastroenterol Hepatol. 2024 Jun 17. doi: 10.1111/jgh.16645.
    >> Share

  226. HO CT, Fu CC, Tan EC, Kao WY, et al
    The association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy.
    J Gastroenterol Hepatol. 2024 Jun 12. doi: 10.1111/jgh.16640.
    >> Share

  227. WURSTLE S, Schneider T, Karapetyan S, Hapfelmeier A, et al
    LINAS-Score: prognostic model for mortality assessment in patients with cirrhotic liver and infected ascites.
    J Gastroenterol Hepatol. 2024 Jun 5. doi: 10.1111/jgh.16637.
    >> Share

  228. LEE KJ, Moon JS, Lim JG, Huh H, et al
    PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children.
    J Gastroenterol Hepatol. 2024;39:1172-1182.
    >> Share

    May 2024
  229. HAYASHI M, Abe K, Sugaya T, Takahata Y, et al
    A low baseline serum myostatin concentration is associated with poor clinical outcome in patients with primary biliary cholangitis.
    J Gastroenterol Hepatol. 2024 May 30. doi: 10.1111/jgh.16639.
    >> Share

  230. SUN Z, Guo Y, Xu X, Zhou C, et al
    Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-associated mitochondrial apoptotic pathway.
    J Gastroenterol Hepatol. 2024 May 28. doi: 10.1111/jgh.16635.
    >> Share

  231. SHIN SK, Oh S, Chun SK, Ahn MJ, et al
    Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 May 27. doi: 10.1111/jgh.16584.
    >> Share

  232. LIU S, Gou H, Wei H, Chen S, et al
    Cholecystohepatic shunt pathway reduces secondary bile acid accumulation to enhance natural killer T cell-mediated anti-hepatocellular carcinoma immunity.
    J Gastroenterol Hepatol. 2024 May 15. doi: 10.1111/jgh.16548.
    >> Share

  233. KOUNTOURAS J, Zavos C, Vardaka E, Kyrailidi F, et al
    Helicobacter pylori and metabolic syndrome-related adipokines in nonalcoholic fatty liver disease pathophysiology.
    J Gastroenterol Hepatol. 2024 May 9. doi: 10.1111/jgh.16621.
    >> Share

  234. LIM J, Kim JH, Kim SE, Han SK, et al
    Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using prospective KACLiF cohort.
    J Gastroenterol Hepatol. 2024 May 8. doi: 10.1111/jgh.16591.
    >> Share

  235. LEE J, Jin YJ, Shin SK, Kwon JH, et al
    Clinical outcomes of transarterial chemoembolization in Child-Turcotte Pugh class A patients with a single small (
    J Gastroenterol Hepatol. 2024 May 6. doi: 10.1111/jgh.16581.
    >> Share

  236. ENDO K, Kakisaka K, Abe T, Yusa K, et al
    Positive impact of obesity on the prognosis of liver cirrhosis.
    J Gastroenterol Hepatol. 2024 May 3. doi: 10.1111/jgh.16590.
    >> Share

  237. LEE S, Choi J, Park JH, Lim CY, et al
    Dynamic liver volume change in predicting hepatic decompensation and long-term effects of stereotactic body radiation therapy.
    J Gastroenterol Hepatol. 2024 May 2. doi: 10.1111/jgh.16588.
    >> Share

  238. ZHONG W, Xu B, Lu Y, Chang J, et al
    Postoperative adjuvant chemotherapy is important for improving long-term survival in patients with colorectal cancer liver metastases undergoing simultaneous resection.
    J Gastroenterol Hepatol. 2024;39:908-919.
    >> Share

  239. PEI X, Jiang W, Li L, Zeng Q, et al
    Mendelian-randomization study revealed causal relationship between nonalcoholic fatty liver disease and osteoporosis/fractures.
    J Gastroenterol Hepatol. 2024;39:847-857.
    >> Share

  240. MAKRI ES, Evripidou K, Polyzos SA
    Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2024;39:806-817.
    >> Share

    April 2024
  241. QI S, Wei X, Zhao J, Wei X, et al
    Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis.
    J Gastroenterol Hepatol. 2024 Apr 30. doi: 10.1111/jgh.16589.
    >> Share

  242. CAO QH, Liu H, Yan LJ, Wang HC, et al
    Role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Apr 30. doi: 10.1111/jgh.16558.
    >> Share


  243. Retraction: Rami Al Batran, Fouad Al-Bayaty, Mahmood Ameen Abdulla, Mazen M Jamil Al-Obaidi, Maryam Hajrezaei, Pouya Hassandarvish, Mustafa Fouad, Shahram Golbabapour, Samaneh Talaee. Gastroprotective effects of Corchorus olitorius. J Gastroenterol He
    J Gastroenterol Hepatol. 2024 Apr 26. doi: 10.1111/jgh.16551.
    >> Share

  244. GRYZIAK M, Kraj L, Stec R
    The role of tumor-associated macrophages in hepatocellular carcinoma-from bench to bedside: A review.
    J Gastroenterol Hepatol. 2024 Apr 23. doi: 10.1111/jgh.16564.
    >> Share

  245. LOON E, Narvaez-Barbecho C, Ortiz JP, Balderramo D, et al
    Impact of self-reported ancestry on the epidemiology of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Apr 13. doi: 10.1111/jgh.16578.
    >> Share

  246. LIU Y, Hu Y, Li B, Su R, et al
    Innate lymphoid cell subsets in the pathogenesis of primary biliary cholangitis.
    J Gastroenterol Hepatol. 2024 Apr 12. doi: 10.1111/jgh.16547.
    >> Share

  247. OHAMA H, Hiraoka A, Tada T, Kariyama K, et al
    Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
    J Gastroenterol Hepatol. 2024 Apr 11. doi: 10.1111/jgh.16553.
    >> Share

  248. CHAN WK, George J
    Metabolic fatty liver syndromes: where do we stand in 2024?
    J Gastroenterol Hepatol. 2024;39:613-614.
    >> Share

  249. PARENTE A, Milana F, Hajibandeh S, Hajibandeh S, et al
    Clinical outcomes after transplantation of domino grafts or standard deceased donor livers: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:620-629.
    >> Share

    March 2024
  250. WANG X, Liu H, Wang Y, Wang P, et al
    Novel protein C6ORF120 promotes liver fibrosis by activating hepatic stellate cells through the PI3K/Akt/mTOR pathway.
    J Gastroenterol Hepatol. 2024 Mar 24. doi: 10.1111/jgh.16538.
    >> Share

  251. SUZUKI K, Yasui Y, Tsuchiya K, Matsumoto H, et al
    Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    J Gastroenterol Hepatol. 2024 Mar 17. doi: 10.1111/jgh.16532.
    >> Share

  252. BALE G, Kulkarni AV, Padaki NR, Menon PB, et al
    Comparing rare variants versus common in the pathogenesis of nonalcoholic fatty liver disease: a whole exome sequencing approach.
    J Gastroenterol Hepatol. 2024;39:587-595.
    >> Share

    February 2024
  253. SOGABE M, Okahisa T, Kagawa M, Sei M, et al
    Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study.
    J Gastroenterol Hepatol. 2024 Feb 29. doi: 10.1111/jgh.16530.
    >> Share


  254. Correction to "Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis".
    J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16529.
    >> Share

  255. TADA T, Kumada T, Hiraoka A, Kariyama K, et al
    mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response.
    J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16512.
    >> Share

  256. WANG J, Zhang Y, Ma Y, Zhao S, et al
    TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16443.
    >> Share

  257. BATT NM, Rodrigues B, Bloom S, Sawhney R, et al
    Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501.
    >> Share

  258. HAHN JW, Lee H, Shin M, Seong MW, et al
    Diagnostic algorithm for neonatal intrahepatic cholestasis integrating single-gene testing and next-generation sequencing in East Asia.
    J Gastroenterol Hepatol. 2024 Feb 7. doi: 10.1111/jgh.16505.
    >> Share

  259. JI PX, Chen YX, Ni XX, Miao Q, et al
    Effect of triggering receptor expressed on myeloid cells 2-associated alterations on lipid metabolism in macrophages in the development of non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:369-380.
    >> Share

    January 2024
  260. TOYODA H, Tada T, Uojima H, Nozaki A, et al
    Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Jan 30. doi: 10.1111/jgh.16494.
    >> Share

  261. AMJAD W, Jiang Z, Lai M
    Statin use in cirrhosis and its association with incidence of portal vein thrombosis.
    J Gastroenterol Hepatol. 2024 Jan 25. doi: 10.1111/jgh.16495.
    >> Share

  262. DIAO L, Wang C, You R, Leng B, et al
    Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    J Gastroenterol Hepatol. 2024 Jan 19. doi: 10.1111/jgh.16463.
    >> Share

  263. ZHU J, Xia Y, Liu X, Zhang C, et al
    Preventing variceal rebleeding in cirrhotic patients with portal vein thrombosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16489.
    >> Share

  264. NIE MT, Wang PQ, Shi PM, Hong XL, et al
    Rifaximin treatment shapes a unique metagenome-metabolism network in patients with decompensated cirrhosis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16484.
    >> Share

  265. SOGABE M, Okahisa T, Kagawa M, Sei M, et al
    Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study.
    J Gastroenterol Hepatol. 2024 Jan 11. doi: 10.1111/jgh.16483.
    >> Share

    December 2023
  266. GOPAL P, Banerjee D, Karad A, Dandi K, et al
    Gastrointestinal: Congenital portosystemic shunt (Abernathy type 2) with cirrhosis of liver.
    J Gastroenterol Hepatol. 2023 Dec 26. doi: 10.1111/jgh.16456.
    >> Share

  267. CHO SH, Song TJ, Oh D, Park DH, et al
    Endoscopic ultrasound-guided hepaticoduodenostomy versus percutaneous drainage for right intrahepatic duct dilatation in malignant hilar obstruction.
    J Gastroenterol Hepatol. 2023 Dec 18. doi: 10.1111/jgh.16442.
    >> Share

  268. TOSHIDA K, Itoh S, Yoshiya S, Nagao Y, et al
    Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Dec 12. doi: 10.1111/jgh.16441.
    >> Share

  269. HUANG X, Zhou LZ, Feng WJ, Liu YQ, et al
    Circ ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 increases the stability of G9a and ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 messenger RNA through recruiting eukaryotic translation
    J Gastroenterol Hepatol. 2023 Dec 7. doi: 10.1111/jgh.16408.
    >> Share

  270. YANG Y, Liu S, Li H, Liu Y, et al
    The protective effect of Nostoc commune Vauch. polysaccharide on alcohol-induced acute alcoholic liver disease and gut microbiota disturbance in mice.
    J Gastroenterol Hepatol. 2023;38:2185-2194.
    >> Share

  271. TONG C, Halengbieke A, Ni X, Han Y, et al
    Bidirectional relationship between nonalcoholic fatty liver disease and serum creatinine-to-body weight ratio as a proxy for skeletal muscle mass index.
    J Gastroenterol Hepatol. 2023;38:2061-2069.
    >> Share

  272. NARANG M, Shah D, Narang S, Gupta N, et al
    Ultrasound-guided aspiration in addition to antibiotics for treatment of liver abscess in children: A randomized controlled trial.
    J Gastroenterol Hepatol. 2023;38:2070-2075.
    >> Share

    November 2023
  273. SHI L, Feng G, Yang X, Zhang Y, et al
    Potential of PAQosome as a therapeutic target for hepatic fibrosis.
    J Gastroenterol Hepatol. 2023 Nov 28. doi: 10.1111/jgh.16427.
    >> Share

  274. DU S, Cao K, Yan Y, Wang Y, et al
    Developments and current status of cell-free DNA in the early detection and management of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16416.
    >> Share

  275. ALLAIRE M, Thabut D
    The applicability of Baveno criteria in the setting of hepatocellular carcinoma remains a controversy.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16415.
    >> Share

  276. FAROOQ U, Tarar ZI, El Alayli A, Kamal F, et al
    Analyzing the utility of renal replacement therapy to manage hepatorenal syndrome in alcoholic hepatitis without liver transplantation: a nationwide analysis.
    J Gastroenterol Hepatol. 2023 Nov 12. doi: 10.1111/jgh.16388.
    >> Share

  277. SUN J
    Navigating the complex landscape of non-alcoholic fatty liver disease: From genomic associate to the AMPK/mTOR pathways.
    J Gastroenterol Hepatol. 2023;38:1863-1864.
    >> Share

  278. TIAN Y, Wang B
    Unraveling the pathogenesis of non-alcoholic fatty liver diseases through genome-wide association studies.
    J Gastroenterol Hepatol. 2023;38:1877-1885.
    >> Share

  279. WANG Y, Huang Y, Zheng T, Sun C, et al
    Gastrointestinal hospitalization during COVID-19 pandemic in the United States: Analysis of a nationwide inpatient sample.
    J Gastroenterol Hepatol. 2023;38:1971-1979.
    >> Share

  280. TAKAHASHI A, Takahata Y, Kokubun M, Anzai Y, et al
    Association between equol and non-alcoholic fatty liver disease in Japanese women in their 50s and 60s.
    J Gastroenterol Hepatol. 2023;38:1958-1962.
    >> Share

  281. MARCONDES-DE-CASTRO IA, Reis-Barbosa PH, Marinho TS, Aguila MB, et al
    AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression.
    J Gastroenterol Hepatol. 2023;38:1868-1876.
    >> Share

    October 2023
  282. QUAN Y, Shou D, Yang S, Cheng J, et al
    Mdivi1 ameliorates mitochondrial dysfunction in non-alcoholic steatohepatitis by inhibiting JNK/MFF signaling.
    J Gastroenterol Hepatol. 2023 Oct 15. doi: 10.1111/jgh.16372.
    >> Share

  283. OH JH, Saeed WK, Kim HY, Lee SM, et al
    Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis.
    J Gastroenterol Hepatol. 2023 Oct 9. doi: 10.1111/jgh.16368.
    >> Share

  284. GIRI S, Singh A, Kolhe K, Kale A, et al
    Reply: Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Oct 7. doi: 10.1111/jgh.16378.
    >> Share

  285. SHOU D, Luo Q, Tang W, Cao C, et al
    Hepatobiliary and pancreatic: Multi-donor fecal microbiota transplantation attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut microbiota.
    J Gastroenterol Hepatol. 2023 Oct 3. doi: 10.1111/jgh.16359.
    >> Share

  286. ITO T, Morooka H, Takahashi H, Fujii H, et al
    Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning.
    J Gastroenterol Hepatol. 2023;38:1832-1839.
    >> Share

  287. VAZ K, Kemp W, Majeed A, Lubel J, et al
    Non-alcoholic fatty liver disease prevalence in Australia has risen over 15 years in conjunction with increased prevalence of obesity and reduction in healthy lifestyle.
    J Gastroenterol Hepatol. 2023;38:1823-1831.
    >> Share

  288. RONG L, Ch'ng D, Jia P, Tsoi KKF, et al
    Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:1682-1694.
    >> Share

  289. TAKAHASHI Y, Seko Y, Yamaguchi K, Takeuchi K, et al
    Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2023;38:1743-1749.
    >> Share

    September 2023
  290. KANG SH, Kim MY, Han SK, Baik SK, et al
    Subclinical diabetes confirmed by 75-g OGTT influence on the prognosis of decompensated cirrhosis.
    J Gastroenterol Hepatol. 2023 Sep 11. doi: 10.1111/jgh.16327.
    >> Share

  291. HIRATA K, Yamamoto Y, Hatanaka K, Kinoshita K, et al
    Hepatobiliary and pancreatic: Tiny pigmented intra-hepatic ducts stones as the cause of jaundice and liver failure.
    J Gastroenterol Hepatol. 2023 Sep 8. doi: 10.1111/jgh.16350.
    >> Share

  292. MURAKAMI S, Uchida T, Imamura M, Suehiro Y, et al
    Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failure.
    J Gastroenterol Hepatol. 2023;38:1637-1646.
    >> Share

  293. HAN E, Chun HS, Lee YH, Lee JS, et al
    MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
    J Gastroenterol Hepatol. 2023;38:1598-1609.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016